Summary The site of action of aminoglutethimide (AG) has been investigated. An Aminoglutethimide (AG) in combination with hydrocortisone (HC) is an effective endocrine therapy in advanced postmenopausal breast cancer, producing a response rate and duration similar to tamoxifen (Smith et al., 1981) . AG was introduced into the treatment of breast cancer as an inhibitor of adrenal steroid production. One site of action is the earliest step in the adrenal conversion of cholesterol to pregnenolone (20,22 desmolase) (Dexter et al., 1967) . AG treatment regimes are currently designed to inhibit this step and HC is added in replacement doses to prevent a reflex rise in ACTH secretion (Santen et al., 1974) . However, AG has another site of action, the inhibition of the conversion of androgens to oestrogens in peripheral tissues tissues (Figure 1) , which is the main source of oestrogen in the postmenopausal woman . AG can also inhibit 1 1-fJ-hydroxylase (Faglia et al., 1971) .
Aminoglutethimide (AG) in combination with hydrocortisone (HC) is an effective endocrine therapy in advanced postmenopausal breast cancer, producing a response rate and duration similar to tamoxifen (Smith et al., 1981) . AG was introduced into the treatment of breast cancer as an inhibitor of adrenal steroid production. One site of action is the earliest step in the adrenal conversion of cholesterol to pregnenolone (20,22 desmolase) (Dexter et al., 1967) . AG treatment regimes are currently designed to inhibit this step and HC is added in replacement doses to prevent a reflex rise in ACTH secretion (Santen et al., 1974) . However, AG has another site of action, the inhibition of the conversion of androgens to oestrogens in peripheral tissues tissues (Figure 1) , which is the main source of oestrogen in the postmenopausal woman . AG can also inhibit 1 1-fJ-hydroxylase (Faglia et al., 1971) .
One of the factors limiting the use of AG is the side effects that occur at conventional dose levels (250mg 4 times a day). In one series of 190 patients, 58% had transient side effects, 9.5% needed to reduce the dose and 5% discontinued the drug showed that aromatisation in vitro is at least 10 times more sensitive than desmolase to inhibition by AG. We have therefore studied the site of action of AG in postmenopausal patients with advanced breast cancer receiving AG and HC therapy in conventional doses and investigated the endocrine effects of low doses of AG alone. Oestrone, oestradiol, DHA-S, 4A androstenedione and 17 OH-progesterone were all measured by immunoassay as described previously (Harris et al., 1982a, b) . However, in this work a chromatography step was included in the oestrone analysis prior to immunoassay. This involved the use of Sephadex LH-20 columns (7 cm long, in short-form pasteur pipettes) with methylene chloride:methanol (95:5) as solvent (Murphy, 1971) . The results were corrected according to the recovery of -103 c.p.m. of [2, 4, 6, 7 -3H] oestrone (Amersham International), which was added to serum samples 18 h before extraction. Cortisol was measured using reagents provided by the WHO Matched Reagent Scheme and according to WHO recommended methodology (WHO Manual 1981) . The intra-and inter-assay coefficients of variation were 7.2 and 14.6 respectively. Only 1 patient showed a normal rise in cortisol levels. As a group, these did not change significantly (paired t-test, Mann-Whitney U test). In 4/10 patients, the post-stimulation levels were <500 nM 1-' (Figure 4 ). Oestrone and DHA-S levels did not change significantly. These results suggested that the desmolase enzyme (Figure 1) HC was added. She has had stable disease for >6 months. Ten patients had their dose increased to 500mg b.d. Two could not tolerate the dose and reduced the dose to 250mg a.m., 500mg p.m.
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The results are thus described for 13 patients in week 1, 12 patients in week 2, 10 patients in week 3 and 8 patients in week 4. Three patients were maintained on lower doses of AG and had HC added.
Because patients with recurrent disease were being studied, the protocol of drug administration was designed so that all the patients would be on maximally tolerated doses of AG plus HC by 1 month from the start of the study. Thus, response to low dose AG alone could not be assessed but 4/11 patients who continued AG responded (1 complete response, 1 partial response, 2 disease stabilisations for >6 months).
Low dose aminoglutethimide alone
Endocrine results Oestrone levels were significantly suppressed in all 13 patients (P=0.015) by the lowest dose of AG alone (125mg b.d.) ( Figure 5 ). Increasing doses and addition of HC did not suppress oestrone further (Table I) . Oestradiol suppression paralleled oestrone suppression ( Figure  5 ). Aminoglutethimide dose (mg) Figure 5 Endocrine effects of incremental low dose aminoglutethimide alone and after the addition of hydrocortisone. Results are means +s.e. at each point. P values are unpaired t tests comparing the effects of the given dose with the pretreatment values. The hormone levels were measured after the patients had been on the given dose of drugs for week. Dosage was increased at weekly intervals. There are no significant differences between any columns.
DHA-S levels were not suppressed by any dose of AG, but fell by 75% when HC was added ( Figure   5 ). Cortisol levels were not affected by AG alone and did not rise when HC was added ( Figure 5 ). A4 androstenedione and 17 OH progesterone levels rose progressively as the dose of AG was increased ( Figures 5 and 6 ). After the addition of HC, the levels fell to levels which were not significantly different to basal values. hydroxylase. However, Taylor et al. (1978) showed that 11 deoxycortisol levels rise in patients taking AG, which suggests that 11 hydroxylase is the more likely site of block. Heterozygotes for congenital adrenal hyperplasia with partial 21 hydroxylase deficiency show a marked rise in 17 OH progesterone after Synacthen tests, although not to the levels found in our patients (Lee & Gareis, 1975; Mauseth et al., 1980) . showed that A4 androstenedione and 17 OH progesterone were not significantly suppressed by AG and HC, although the precursors DHA and 17 OH pregnenolone were markedly suppressed. They suggested that this phenomenon could be explained by increased activity of 3 fol dehydrogenase. However, in our study with Synacthen the percentage rise in 17 OH progesterone is much greater than the rise in A4 androstenedione and there is a marginally significant correlation with the rise in A4 androstenedione. 11/3 hydroxylase inhibition with the accumulation of the precursor 17 OH progesterone is an alternative explanation for the rise in A4 androstenedione.
Vermeulen (1976) studied 10 normal postmenopausal women on no treatment and found a 5-fold increase in 17 OH progesterone and a 1.8-fold increase in A4 androstenedione on Synacthen stimulation. These rises are less than half of those we found. Oestrone also rose in those patients, although in our patients there was no rise in oestrone. Kruyt & Rolland (1982) also found increases in A4 androstenedione and 17 OH progesterone in normal women on no treatment, but again these were less in amplitude than those found in our study. This difference is probably because the normal women were not taking AG and our patients were. Because of the block in conversion of 17 OH progesterone to cortisol, the levels of 17 OH progesterone rose higher in our own patients, as did A4 androstenedione levels.
The low dose AG study was undertaken because the failure of oestrone to increase on Synacthen stimulation suggested that the main site of action of AG for inhibiting oestrone production is the peripheral aromatase system rather than adrenal steroidogenesis. The lowest dose of AG studied suppressed oestrone and oestradiol levels as much as the full dose of 500mg b.d. with HC 20mg b.d. The oestrone suppression was maintained in the presence of increasing A4 androstenedione levels in weeks 1, 2 and 3 after starting AG. The increase in A4 androstenedione and 17 OH progesterone with increasing dosage of AG, without a fall in DHA-S, suggests that desmolase is not inhibited and that with increasing AG there is increasing blockade of 1 l,B hydroxylase and/or increasing activity of 3 Pol dehydrogenase. Aromatase appears to be maximally inhibited by the lowest dose.
The progressive increases are unlikely to be due to time on treatment, since the Synacthen tests show the adrenal can respond within 30min to a change in stimulus, and within one week of adding a replacement dose of HC the 17 OH progesterone and A4 androstenedione levels had returned to normal. AG has a plasma half-life of 7-12 h (Murray et al., 1979) , which should lead to the attainment of a new steady state within one week of each dose increment. AG induces its own metabolism (Murray et al., 1979) , but this probably occurs within the first week, as no changes in plasma levels were detected between 1 and 12 weeks of therapy (Murray et al., 1979) .
There was no significant suppression of DHA-S until HC was added. AG alone does not maintain DHA-S suppression and DHA-S cannot therefore be used as a marker for the endocrine effects of AG. Several studies that have used DHA-S as a monitor for AG Coombes et al., 1982; Murray et al., 1981) will need to be reassessed. Santen et al. (1982) found that in clinical non-responders to AG therapy, DHA-S levels were higher than in responders. This is unlikely to reflect differences in AG levels, but rather the effects of HC. Similarly, the potency of the D-isomer was compared with 1000mg of racemic AG and considered to be twice as active ) but our results show that 250mg of racemic AG is as potent as 1000mg. The relative potency of D-aminoglutethimide in vivo is thus unknown.
The cortisol levels remained the same after addition of HC, showing that 20mg twice a day was a replacement dose for the patients studied. The fall in 17 OH progesterone and A4 androstenedione is probably due to suppression of the increased ACTH drive following inhibition of llI# hydroxylase by AG. Increased ACTH drive is likely because a block of conversion of 17 OH progesterone to cortisol should produce a rise in 17 OH progesterone and a fall in cortisol, unless increased ACTH drive raised precursors sufficiently to overcome the block and reach a new steady state with normal cortisol and raised precursors.
All 13 patients tolerated the lowest dose of AG without side effects but 3/11 patients who had dose increments could not tolerate the full dose. These endocrine studies show that in patients with advanced breast cancer, AG acts biochemically by inhibiting the conversion of A4 androstenedione to oestrone in peripheral tissues, rather than by adrenal suppression. Peripheral aromatisation is much more sensitive than the adrenal desmolase to inhibition by AG, so lower doses can be used.
These studies provide the endocrine basis for further investigation of the clinical response to low dose AG alone. This dosage regimen should be less toxic, as well as producing a novel manipulation of the endocrine environment (a rise in androgens and fall in oestrogens). The twice daily low dose regime may be useful in adjuvant therapy and combination endocrine therapy as well as in advanced disease.
